Skip to main content
. 2017 Mar 8;37(4):2007–2015. doi: 10.3892/or.2017.5495

Figure 2.

Figure 2.

Lower doses of curcumin induce CRABPII expression level in TNBC cell lines. (A) Total RNA was collected from MDA-MB-231 and (C) MDA-MB-468 cells treated with 5 or 10 µM curcumin for 4 h (DMSO was used as control). (A) Expression level of CRABPII mRNA in MDA-MB-231 cells and (C) MDA-MB-468 cells were analyzed by qRT-PCR. GAPDH was used for normalization. Data are mean ± SE (n=3). (A) *p=0.005 (5 µM curcumin treatment compared to the control), **p=0.001 (10 µM curcumin treatment compared with its respective control). (C) #p=0.047 (5 µM curcumin treatment compared to the control), ##p=0.006 (10 µM curcumin compared with its respective control). (B) MDA-MB-231 and (D) MDA-MB-468 cells were treated with 5 or 10 µM curcumin for 24 h (DMSO was used as control) prior to cell lysis. Cell lysates were resolved with SDS-PAGE and immunoblotted with antibodies recognizing CRABPII, and GAPDH was used as a loading control. CRABPII, cellular retinoic acid-binding protein II; TNBC, triple-negative breast cancer.